The Construction Zone Conundrum: Waymo Restricts Freeway Rides After Robotaxis Blunder Into Bay Area Work Zones

 

 The Construction Zone Conundrum: Waymo Restricts Freeway Rides After Robotaxis Blunder Into Bay Area Work Zones

**Subtitle:** *From a 70 MPH nightmare to a 3,871-vehicle recall, the incident exposes the hidden complexities of autonomous driving—and leaves passengers questioning the safety of the "driverless" future.*

**Reading Time:** 7 Minutes | **Category:** Technology & Safety

## Introduction: The 70 MPH Nightmare

Elliot Slade was five minutes into a routine Waymo ride along Highway 101 in the San Francisco Bay Area when the car "started freaking out." He watched as the robotaxi, which had no human behind the wheel, ignored flashing lights, warning signs, and orange cones. It drove right through a construction zone and accelerated to highway speeds .

"There were signs. There were lights. There were cones. And it went through the cones and then sped up straight away," Slade told ABC7 . A nearby highway patrol car began chasing them, lights flashing, with officers shouting, "Stop Waymo. Stop Waymo." The passengers were terrified.

Slade and his fiancée survived. But the incident, which occurred in May, is one of at least 13 that forced Waymo to pull its robotaxis off freeways and issue its second recall in just over a month . The company is now restricting freeway rides while it works on a software fix for **3,871 vehicles** equipped with its fifth-generation automated driving system .

This is not just a technical glitch. It is a stark reminder that autonomous vehicles are still learning to navigate the unpredictable, messy, and ever-changing realities of American roadways—and that the path to a driverless future is littered with orange cones.

In this deep-dive, we will break down what went wrong, hear from the passengers who lived through the nightmare, and explore what this recall means for the future of robotaxis in the U.S.

> **The Bottom Line Up Front:** Waymo has recalled nearly 4,000 robotaxis after multiple vehicles entered closed freeway construction zones in Phoenix and the Bay Area. The issue stems from a software flaw that caused the cars to either prioritize other hazards over construction zone recognition or fail to recognize the zones entirely. The company has restricted freeway driving while it develops a software patch, but the incident has shaken public confidence and raised questions about the readiness of autonomous technology for complex road environments .

## Part 1: What Happened—The 13 Incidents That Triggered the Recall

The recall was triggered by a series of incidents in April and May across two states.

### The Phoenix Failures (April 2026)

In mid-April, Waymo vehicles in Phoenix failed to recognize ramp-closure signs and drove straight past them into active construction areas . The Field Safety Committee reviewed one event from April 11 and five events from April 19 in which autonomous vehicles drove past signs into planned freeway construction zones .

### The San Francisco Bay Area Breaches (May 2026)

The most dramatic incidents occurred on May 18. Seven Waymo vehicles in the San Francisco Bay Area entered freeway lanes with active construction by driving between cones designating a lane closure in an adjacent lane . This happened across a single day, suggesting a systemic software flaw rather than isolated anomalies.

### Elliot Slade's Terrifying Ride

Elliot Slade and his fiancée were passengers on one of those Bay Area Waymos. As they approached a construction zone, the car began "freaking out" . "One lane was gone, another lane was, who knows where it was," Slade told CBS News. "Cars were all over the place going in" .

The car accelerated to 70 MPH down a construction lane. "There were construction signs. There were lights going on. Police in the distance, and it sped up," Slade said. "That's when I looked at my fiancée, we're done. This is it. We're dead. We're going to die right here in the Waymo" .

The Waymo eventually exited the freeway into a residential neighborhood and stopped. Slade said Waymo offered him three free rides, each worth up to $40, but he was unsure if he would use them .

| Incident Location | Date | Number of Incidents | Key Detail |

| :--- | :--- | :--- | :--- |

| Phoenix, AZ | April 11 & 19 | 6 | Vehicles drove past ramp-closure signs |

| San Francisco Bay Area, CA | May 18 | 7 | Vehicles drove between cones into construction zones |

*Sources: *

## Part 2: The Software Flaw—Why the Cars Stopped Seeing Cones

The National Highway Traffic Safety Administration (NHTSA) recall report provides a detailed explanation of what went wrong.

### The Dual Failure Mode

According to the filing, the vehicles may have entered construction zones for two reasons:

1. **Inappropriately prioritizing the avoidance of other freeway hazards:** The car's software may have been distracted by other vehicles or obstacles, causing it to miss the construction zone .

2. **Failing to recognize the construction zone entirely:** In some cases, the system simply did not detect the cones, signs, or lights .

"Under certain circumstances, the [autonomous vehicle] may enter and drive at speed in freeway construction zones due to inappropriately prioritizing the avoidance of other freeway hazards and/or failing to recognize the construction zone," the recall notice states .

### The Scope of the Recall

The recall covers **3,871 vehicles** equipped with Waymo's fifth-generation automated driving system, manufactured between March 17, 2022, and May 19, 2026 . All 3,871 vehicles are believed to have the defect .

### The Temporary Fix

Waymo restricted freeway driving on May 19, 2026, the day after the Bay Area incidents . The company's Safety Board reviewed the issue on June 1, requested more information, and decided on June 8 to conduct a recall . NHTSA acknowledged the recall on June 17 .

The permanent fix—a software update that will enable the vehicles to detect when they are in a construction zone and avoid entering one—is still under development .

## Part 3: The Passenger Experience—A "100% Not Ready" Verdict

The recall is a technical story, but the human impact is what gives it weight.

### "We Felt Completely Helpless"

Slade was candid about his experience. "What was scary was that for the first time, we felt completely helpless," he told KPIX-TV . "You can't jump into the seat. No one was picking up. It was going at 70 on this construction lane into what we thought were like trucks. And police and everything" .

He described the moment he realized the car was not going to stop: "There was a moment where even getting into it again was kind of freaky. A bit of PTSD—yeah" .

### The "PTSD" Effect

Slade said he has only used Waymo once since the incident. "I don't want to use it again," he told ABC7 . His experience highlights a critical challenge for autonomous vehicle companies: even one terrifying ride can permanently erode passenger trust.

### The Public Safety Concern

The incident also raised public safety concerns. Slade noted that if something else had gone wrong, "someone in that road might have got hit. We might have crashed in the car" . The fact that a highway patrol car had to chase the vehicle underscores the real-world risks of autonomous failures.

## Part 4: The Recall History—This Is Not Waymo's First Software Glitch

The construction zone recall is the latest in a series of safety actions involving Waymo vehicles .

### The Floodwater Incident

The company previously recalled vehicles after some drove into standing water or flooded roadways . In May 2026, Waymo issued a recall after one of its robotaxis drove into a flooded street in San Antonio .

### The May Recall

The construction zone recall is Waymo's sixth overall and its **second in just over a month** . The frequency of recalls suggests that the technology, while advancing, is still grappling with fundamental challenges in perception and decision-making.

### The NHTSA Scrutiny

The National Highway Traffic Safety Administration has been closely monitoring Waymo's progress. The agency's acknowledgment of the recall and its detailed description of the defect highlight the regulatory scrutiny that autonomous vehicles face.

## Part 5: The Waymo Response—What the Company Is Saying

Waymo has been quick to characterize the issue as a "voluntary" recall and an "area of improvement."

### The Official Statement

"We identified an area of improvement regarding performance around freeway construction zones," a Waymo spokesperson said . "We voluntarily restricted freeway operations last month while making improvements, proactively notified state and federal regulators, and decided to file a voluntary software recall with NHTSA" .

The company emphasized that it "continues to safely serve riders on surface streets in all the cities where we operate" .

### The "Voluntary" Debate

Waymo frames the recall as voluntary, suggesting proactive responsibility. However, the NHTSA filing was prompted by 13 documented incidents, raising questions about whether the company would have acted without the public scrutiny.

### The Remedy Timeline

The remedy is currently under development . Waymo has not provided a specific timeline for when the software patch will be deployed or when freeway operations will resume. In the meantime, robotaxis will continue to operate on surface streets, where they are considered safer .

## Part 6: What This Means for the Future of Robotaxis

The Waymo recall is a setback, but it is not a death knell for autonomous vehicles.

### The Construction Zone Challenge

Autonomous vehicles are trained on vast amounts of data, but construction zones are inherently unpredictable. They are temporary, unmarked on maps, and often have conflicting signage. The Waymo incident highlights the difficulty of teaching AI to handle "edge cases."

### Expert Perspective

Scott Moura of UC Berkeley's Institute of Transportation Studies suggested a solution: better data sharing between transportation agencies and autonomous vehicles. "Transportation agencies that are doing construction on highways, they're actively feeding data into these data exchanges that connect to vehicles," he said .

### The Trust Deficit

The recall may slow public adoption of robotaxis. Slade's experience—and his reluctance to ride again—is likely shared by many. Autonomous vehicle companies will need to rebuild trust through transparency, safety, and, ultimately, flawless performance.

### The Industry Impact

Waymo is the U.S. robotaxi leader. Its failures will be closely watched by regulators, competitors, and the public. The recall may delay the expansion of autonomous freeway driving, which Waymo had only introduced seven months prior .

## Frequently Asked Questions (FAQ)

**Q: Why did Waymo recall nearly 4,000 robotaxis?**

A: Waymo recalled 3,871 vehicles because their software could fail to recognize freeway construction zones, causing the cars to enter active work areas and continue driving at speed . The NHTSA identified a risk of collision as the primary safety concern .

**Q: How many incidents triggered the recall?**

A: There were 13 known incidents. Six occurred in Phoenix, Arizona, in April, and seven occurred in the San Francisco Bay Area in May .

**Q: Is Waymo still operating?**

A: Yes. Waymo has restricted freeway driving but continues to operate on surface streets in its service areas .

**Q: Has a permanent fix been implemented?**

A: Not yet. Waymo said a software remedy is "currently under development" . In the meantime, the company is preventing its vehicles from accessing freeways.

**Q: Is this Waymo's first recall?**

A: No. This is Waymo's sixth recall and its second in just over a month. The company previously recalled vehicles after they drove into floodwaters .

**Q: Are passengers still safe in Waymo vehicles?**

A: Waymo has stated that it continues to "safely serve riders on surface streets" . However, the recall highlights the importance of ongoing safety monitoring. Passengers should remain aware of their surroundings and report any concerning behavior to the company.

**Q: What caused the software to fail?**

A: According to NHTSA, the vehicles either "inappropriately prioritiz[ed] the avoidance of other freeway hazards" or "fail[ed] to recognize the construction zone" entirely .

**Q: When will Waymo resume freeway operations?**

A: The company has not provided a specific timeline. Freeway service will resume once the software fix is developed, tested, and deployed .

**Q: Will my Waymo ride be affected?**

A: If you are in a city where Waymo operated on freeways (San Francisco, Los Angeles, Phoenix, Miami), your ride will now be restricted to surface streets until the software is fixed .

**Q: What did passengers say about the incident?**

A: Elliot Slade, who was a passenger during one of the Bay Area incidents, described the experience as terrifying and said he was not sure if he would ever ride again .

## Conclusion: The Cones Are Still Winning

We started this article with a story—Elliot Slade’s terrifying 70 MPH ride through a construction zone.

We end with a reality check: the robotaxis are getting smarter, but they are not yet smart enough to handle the unpredictable, messy, and ever-changing reality of American roadways.

The construction zone recall is a bump in the road. It is not the end of autonomous vehicles, nor even the end of Waymo. The company continues to operate on surface streets, and its technology is still the most advanced in the U.S.

But the incident is a reminder that the "driverless future" is still in beta. The cars can handle the open highway, but they can’t always handle the orange cones. And until they can, passengers will continue to wonder whether the technology is ready for the real world.

**For the Passenger:**

If you ride in a Waymo, remain aware of your surroundings. Pay attention to the route and the environment. If something seems wrong, contact support immediately. The cars are safer than human drivers in most situations, but they are not infallible.

**For the Technology Advocate:**

This recall is not a failure; it is a learning opportunity. The autonomous vehicle industry is still young, and setbacks are inevitable. The key is to address them transparently and improve the technology.

**For the Skeptic:**

The incident validates concerns about the safety of autonomous vehicles. Regulation and oversight are essential to ensure that the technology develops responsibly.

**For the Investor:**

Waymo is still the leader in the robotaxi space, but the recall underscores the risks of investing in autonomous technology. Watch for the resolution of the software fix and the company’s ability to restore public trust.

**The Bottom Line:**

Waymo recalled nearly 4,000 robotaxis after multiple vehicles entered freeway construction zones in Phoenix and the Bay Area. The issue stems from a software flaw that caused the cars to either prioritize other hazards or fail to recognize construction zones. The company has restricted freeway driving while developing a fix. The incident has shaken passenger confidence and highlighted the challenges of autonomous driving in complex environments.

The orange cones are still winning. But the technology is still learning.

---

**#Waymo #Robotaxi #AutonomousVehicles #SelfDrivingCars #Recall #NHTSA #AI #Transportation #Safety**

--read also-

*Disclaimer: This article is for informational purposes only. It does not constitute safety or legal advice. The software fix for Waymo's construction zone issue is currently under development. Always follow the safety guidelines provided by autonomous vehicle operators.*

The End of the Egg: FDA Panel Unanimously Backs Moderna's mRNA Flu Vaccine—A Game-Changer for Flu Season

 

 The End of the Egg: FDA Panel Unanimously Backs Moderna's mRNA Flu Vaccine—A Game-Changer for Flu Season

**Subtitle:** *From a 27% efficacy boost to a 3-month production timeline, the first mRNA flu shot just cleared its biggest hurdle. Here is why experts say this is the "future of influenza prevention."*

**Reading Time:** 7 Minutes | **Category:** Health & Science

## Introduction: The Flu Shot Just Got a Major Upgrade

For decades, the flu shot has been a game of educated guesswork. Every year, scientists pick the strains they think will circulate, grow them in eggs, and hope they match. When they are wrong, effectiveness can plummet to as low as 19%.

On Thursday, June 18, 2026, that century-old process took a major step toward obsolescence.

The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted **unanimously 9-0** to recommend Moderna's mRNA-based influenza vaccine, mFlusiva (mRNA-1010), for adults aged 50 and older . It is the first time a flu vaccine using the same mRNA technology that revolutionized COVID-19 prevention has received such a strong endorsement.

"This also puts us in a position, having this technology available, to be better prepared for emerging strains or pandemic strains in the future," said Dr. Flor Munoz-Rivas of Baylor College of Medicine, a member of the advisory committee .

The decision marks a dramatic turnaround for a vaccine that faced significant political and regulatory headwinds. The FDA had initially refused to review Moderna's application before reversing course . The Trump administration, led by Health Secretary Robert F. Kennedy Jr., had also cut funding for mRNA research and scrutinized vaccine approvals .

But the data was too compelling to ignore.

In this deep-dive, we will break down what makes this vaccine different, how much more effective it is than current shots, and why it could be available for the 2026–2027 flu season.

> **The Bottom Line Up Front:** The FDA's independent advisory committee voted unanimously that the benefits of Moderna's mRNA flu vaccine outweigh its risks for adults 50 and older. The vaccine showed a 26.6% relative efficacy advantage over standard-dose flu shots and demonstrated a broader, longer-lasting immune response than traditional vaccines. A final FDA decision is expected by August 5, 2026, which would make it available for the upcoming flu season if approved.

## Part 1: The Data That Won Over the Panel

The committee's unanimous recommendation was anchored by robust clinical trial data that addressed the limitations of current flu vaccines.

### The 26.6% Advantage

In a Phase 3 trial involving nearly 41,000 adults aged 50 and older, Moderna's mRNA vaccine demonstrated a relative vaccine efficacy of **26.6%** against RT-PCR-confirmed influenza-like illness compared with a standard-dose flu vaccine . When measured against severe outcomes—including emergency room visits, hospitalizations, and urgent care use—the efficacy rose to **47.9%** .

For older adults, who are among the most vulnerable to severe flu complications, a separate immunogenicity study compared mRNA-1010 against Fluzone High-Dose, a vaccine specifically recommended for seniors. The mRNA vaccine met prespecified noninferiority and superiority criteria, with immune responses remaining higher through the six-month follow-up .

### The "Immune Diversification" Advantage

Perhaps the most significant finding came from a Washington University School of Medicine study published in *Nature Immunology* . Researchers found that the mRNA flu vaccine did not just boost immunity against the strains it was designed for—it broadened the antibody response to recognize a wider array of flu viruses.

Among 13 people receiving the mRNA flu vaccine, **five developed persistent, flu-specific germinal center responses in their lymph nodes that lasted for the full 26 weeks of the study** . Such responses were not observed in any of the 15 participants who received the traditional flu shot.

"This can broaden the antibody response and better arm the immune system against an ever-changing virus," said Dr. Ali Ellebedy, the study's senior author .

| Metric | mRNA-1010 | Standard Vaccine | Advantage |

| :--- | :--- | :--- | :--- |

| **Relative Vaccine Efficacy** | ~26.6% | Baseline | **+26.6%** |

| **Severe Outcome Protection** | ~47.9% | Baseline | **+47.9%** |

| **Production Timeline** | 2-3 months | 6 months | **2x faster** |

| **Immune Persistence** | 26+ weeks | Limited | **Longer-lasting** |

| **Strain Breadth** | Broad | Narrow | **More adaptable** |

*Sources: *

## Part 2: The Regulatory Rollercoaster—How Politics Nearly Killed the Vaccine

The path to this unanimous vote was anything but smooth. The vaccine's journey reflects the deep political divisions over mRNA technology that have persisted since the COVID-19 pandemic.

### The Initial Rejection

Earlier in 2026, the FDA, under then-Commissioner Marty Makary and top vaccine official Vinay Prasad, refused to even review Moderna's application . The agency argued that Moderna's clinical trials used a standard-dose comparator for older adults, which they said did not reflect the current standard of care that prioritizes high-dose or adjuvanted vaccines for that demographic .

Public health experts and the biotech industry were furious. The FDA reversed course just two weeks later, but the damage to the agency's credibility was done .

### The Kennedy Factor

Health Secretary Robert F. Kennedy Jr., a longtime anti-vaccine activist, has consistently expressed skepticism toward mRNA technology. Under his leadership, the Department of Health cut nearly **$500 million** in funding for mRNA research projects .

Despite this political pressure, the advisory committee members maintained their scientific independence. "The studies that were presented today were very well conducted. They have very clear results that are very robust," said Dr. Flor Munoz-Rivas .

### The Makary/Prasad Exit

Both Makary and Prasad have since left the agency following a series of controversies over vaccine and rare-disease drug reviews . Acting Commissioner Kyle Diamantas has since moved to stabilize agency operations and repair relations with the biotech sector .

## Part 3: The Science—Why mRNA Flu Vaccines Are Different

To understand why this vaccine is a breakthrough, you have to understand the limitations of traditional flu vaccines.

### The "Strain Mismatch" Problem

Traditional flu vaccines are made by growing inactivated flu viruses in eggs—a process that takes about **six months** from strain selection to available supply . Because of this, the strains for each season are selected months in advance.

When the projections are wrong—as they were in the 2024-2025 season—effectiveness can drop from about 60% in a good year to as low as **19%** .

### The mRNA Advantage

mRNA technology offers two critical advantages:

1. **Speed**: The mRNA production process takes **two to three months**, halving the time needed to respond to emerging strains .

2. **Breadth**: The Washington University study found that the mRNA vaccine induced antibodies that recognized a "broad portfolio" of flu viruses across decades of viral evolution .

"mRNA-1010 has the potential to provide an important new option for seasonal flu prevention and further demonstrate the versatility of our mRNA platform," said Stéphane Bancel, CEO of Moderna .

### The Safety Profile

The committee reviewed safety data from the administration of over 6 billion doses of mRNA technology globally since 2020 . The most common side effects were consistent with mRNA vaccines: injection-site pain (65.8%), fatigue (45.1%), and headache (37.8%) .

No serious safety signals emerged from the Phase 3 program .

## Part 4: The Path Forward—When Will It Be Available?

The unanimous vote is a critical milestone, but it is not the final step.

### FDA Decision by August 5

The FDA has set a target action date of **August 5, 2026** . The agency typically follows the recommendations of its advisory committees, but it is not bound by them.

### The CDC Hurdle

Even after FDA approval, the vaccine will need a recommendation from the CDC's Advisory Committee on Immunization Practices (ACIP) before it can be widely distributed . The ACIP process has faced its own challenges under the current administration.

### The Post-Marketing Study Requirement

For adults 65 and older, Moderna is seeking **accelerated approval**, which requires a large post-marketing confirmatory trial. The company has agreed to enroll up to **800,000 participants** across two flu seasons to confirm the vaccine's benefit in this population .

| Milestone | Date/Status |

| :--- | :--- |

| **VRBPAC Vote** | June 18, 2026 (9-0 in favor) |

| **FDA Decision** | Expected by August 5, 2026 |

| **CDC ACIP Review** | TBD (fall 2026) |

| **Availability** | 2026-2027 flu season (if approved) |

*Sources: *

## Frequently Asked Questions (FAQ)

**Q: What is mFlusiva (mRNA-1010)?**

A: It is Moderna's investigational mRNA-based influenza vaccine, the first flu shot to use the same technology as COVID-19 vaccines. It was endorsed unanimously by the FDA's expert panel on June 18, 2026 .

**Q: How effective is the new mRNA flu vaccine?**

A: In a Phase 3 trial, it demonstrated a 26.6% relative efficacy advantage over standard-dose flu vaccines. Against severe outcomes like hospitalization, the efficacy rose to 47.9% .

**Q: Is it safe?**

A: The safety profile is consistent with other mRNA vaccines. The most common side effects are injection-site pain (65.8%), fatigue (45.1%), and headache (37.8%) . No serious safety concerns were identified .

**Q: Who will be eligible?**

A: Moderna is seeking approval for adults aged 50 and older. The committee recommended it for both the 50-64 and 65+ age groups .

**Q: When will it be available?**

A: The FDA is expected to make a final decision by August 5, 2026. If approved, it could be available for the 2026-2027 flu season .

**Q: Why is mRNA technology better for flu vaccines?**

A: Traditional flu vaccines take about six months to produce and are often mismatched to circulating strains. mRNA vaccines can be manufactured in two to three months and can be updated more quickly to match emerging strains .

**Q: Did the FDA initially reject this vaccine?**

A: Yes. The FDA initially refused to review the application before reversing course under intense public criticism .

## Conclusion: The Flu Shot of the Future

We started this article with a number: 9-0. That is the unanimous vote from the FDA advisory committee.

We end with a different number: **47.9%**. That is the efficacy against severe outcomes—a significant improvement over current flu vaccines.

The unanimous endorsement of Moderna's mRNA flu vaccine is a turning point in influenza prevention. It represents the first time the U.S. has moved toward the "egg-free" future that public health experts have been advocating for years .

**For the Patient:**

If you are 50 or older, this vaccine could offer stronger, broader, and longer-lasting protection than current flu shots—if it is approved by August.

**For the Skeptic:**

The safety data is robust. Over 6 billion doses of mRNA vaccines have been administered globally since 2020 . The independent advisory committee, which included leading experts, concluded the benefits outweigh the risks.

**For the Public Health Advocate:**

The mRNA flu vaccine is a test case for how quickly the U.S. can adopt new technology. If approved, it could pave the way for combination vaccines that protect against flu, COVID-19, and other respiratory viruses in a single shot.

**The Bottom Line:**

The FDA's advisory committee unanimously recommended Moderna's mRNA flu vaccine for adults 50 and older. The vaccine showed a 26.6% efficacy advantage over current flu shots and offers broader, longer-lasting protection. A final FDA decision is expected by August 5, 2026. If approved, it will be available for the 2026–2027 flu season.

The egg-based flu shot era may finally be ending.

---

**#mRNAFluVaccine #Moderna #FluSeason #FDA #PublicHealth #Vaccines #mRNA #Influenza**

read also---

*Disclaimer: This article is for informational purposes only. It does not constitute medical advice. The vaccine is not yet approved by the FDA. Always consult with a healthcare provider for personalized health recommendations.*

The $600 Billion Belly Flop: Why SpaceX Stock Is Tumbling After the Cursor Deal—and How Low It Could Go

 

 The $600 Billion Belly Flop: Why SpaceX Stock Is Tumbling After the Cursor Deal—and How Low It Could Go

**Subtitle:** *From a $225.64 euphoric peak to a $179 pullback, the rocket company just lost $600 billion in market value. Here is why the “meme stock” hype is colliding with the harsh math of dilution and debt.*

**Reading Time:** 8 Minutes | **Category:** Markets & AI

## Introduction: The Record-Breaking Debut That Just Broke

Just one week ago, SpaceX was the undisputed king of Wall Street. Its $135 IPO on June 12 was the largest in history, raising $75 billion and sending the stock on a staggering 50% surge over three sessions to an intraday peak above $225 .

Elon Musk became the world’s first trillionaire. Retail investors poured nearly $370 million into the stock in its first three days—more than four times the flow into Nvidia over the same period . The company briefly ranked fourth globally in market value, ahead of Amazon and Microsoft .

Then, the music stopped.

On June 16, SpaceX announced it would acquire AI coding startup Cursor for **$60 billion** in an all-stock deal . The market reacted swiftly. The stock fell nearly 5% on Wednesday, another 6.4% on Thursday, and has now dropped roughly 20% from its peak, wiping out more than **$600 billion** in market value .

The stock is now trading around **$179–$185**, still above its $135 IPO price, but far from the euphoric highs of Tuesday . The question on every investor’s mind is: How low could it go?

In this deep-dive, we will break down the three forces driving the selloff, analyze the bull and bear cases for the stock, and tell you what to watch next.

> **The Bottom Line Up Front:** SpaceX stock has shed $600 billion in value after the company announced a $60 billion all-stock acquisition of Cursor, diluting existing shareholders by roughly 3.4%. Morningstar has a fair value estimate of $62 per share, while Oppenheimer has raised its target to $250. The stock is caught between a valuation chasm—trading at 94 times sales while losing billions—and a supply wave from an upcoming lockup expiry and a $20 billion bond offering.

## Part 1: The Three Forces Driving the Selloff

### 1. The $60 Billion Dilution Shock

The immediate trigger for the selloff was the Cursor acquisition . SpaceX agreed to pay $60 billion in stock for the AI coding startup, which represents roughly **3.4% dilution** of the company’s IPO valuation .

For investors who bought at $135, the dilution is manageable. For those who chased the stock to $225, it is a painful reality check. The all-stock deal means that existing shareholders now own a smaller piece of the company—and the market is repricing accordingly.

### 2. The Valuation Reality Check

SpaceX was already expensive before the Cursor deal. At its IPO valuation, the company traded at roughly **67 times sales**—about three times Nvidia’s revenue multiple . After the post-IPO surge, that multiple climbed even higher.

Morningstar analysts have been skeptical from the start. They valued SpaceX at just $780 billion pre-IPO—less than half of its listing valuation—and have since lowered their fair value estimate to **$62 per share**, citing the Cursor dilution . In a best-case scenario, Morningstar says shares could reach $169 if AI revenue improves .

Jim Cramer weighed in on X (formerly Twitter), saying SpaceX “could not sustain its meme status” and that “looks like it couldn’t sustain the walk-up” .

### 3. The Supply Wave Looming

Beyond the acquisition, two supply-side pressures are building.

**First, the lockup expiry.** A significant number of insider shares will become eligible for sale in late July, potentially doubling the stock’s free float . This could create selling pressure as early investors cash out.

**Second, the bond offering.** SpaceX’s bankers are preparing to meet investors to discuss a bond offering of at least **$20 billion** . The deal would refinance a bridge loan taken out to fund the xAI acquisition and signal that the company intends to fund its AI expansion through debt, not just equity .

| Pressure Point | Details |

| :--- | :--- |

| **Cursor Dilution** | 3.4% dilution of IPO valuation |

| **Lockup Expiry** | Late July; may double free float |

| **Bond Offering** | At least $20 billion in debt |

*Sources: *

## Part 2: The Bull Case—Why Some Analysts See $250

Despite the selloff, not everyone is bearish.

### Oppenheimer’s $250 Target

Oppenheimer analyst Timothy Horan applauded the Cursor deal, raising his price target to **$250** from $190 . He argued that the acquisition is “beneficial for both sides,” giving Cursor access to SpaceX’s computing infrastructure while SpaceX gains AI technology, engineering talent, training data, and a user base of over one million developers .

“This deal is beneficial for both sides,” Horan wrote, adding that SpaceX “owns every layer of the AI stack, giving it cost and quality advantages” .

### The AI Stack Thesis

SpaceX is positioning itself as a vertically integrated AI powerhouse. It now owns:

- **Hardware:** Launch vehicles and Starlink satellites

- **Compute:** The Colossus supercomputer

- **Model:** xAI (Grok)

- **Application:** Cursor (AI coding assistant)

This vertical integration could create a moat that competitors cannot easily replicate .

### The Meme Stock Defense

Swissquote analyst Ipek Ozkardeskaya argued that SpaceX has emerged as the latest “meme stock,” where investors are buying “in the expectation that others will buy too and push the price higher” . If the retail enthusiasm returns, the stock could rebound.

| Bull Argument | Details |

| :--- | :--- |

| **Oppenheimer Target** | $250 per share |

| **AI Stack Integration** | Vertical integration across hardware, model, application |

| **Retail Enthusiasm** | Meme stock dynamics could return |

*Sources: *

## Part 3: The Bear Case—Why the Stock Could Go Much Lower

### Morningstar’s $62 Fair Value

Morningstar analysts lowered their fair value estimate to **$62 per share** after the Cursor deal . That is less than half of the IPO price and a fraction of the current trading price. The firm has consistently argued that SpaceX is “significantly overvalued” and that its market value is tied to technologies it claims are “novel and untested” .

### The Cash Burn Reality

SpaceX is losing billions. The company reported a net loss of **$4.94 billion in 2025** and another **$4.28 billion in Q1 2026** . Revenue rose 33% to $18.67 billion in 2025, but the losses are mounting as the company scales up AI infrastructure .

The AI business lost **$6.4 billion** in 2025. The rocket business is also losing money . The company has accumulated total losses of **$41.3 billion** since its founding in 2002 .

### The Valuation Professor’s Warning

Aswath Damodaran, the “Dean of Valuation” at NYU, called the **$28.5 trillion total addressable market** cited in SpaceX’s prospectus a “hallucination” during CNBC’s IPO coverage .

Veteran hedge fund manager Doug Kass, who planned to short the stock, cited research showing that companies debuting above 40 times sales underperform the market by 58% over the following three years . SpaceX was priced at approximately 94 times revenue at the IPO .

| Bear Argument | Details |

| :--- | :--- |

| **Morningstar Fair Value** | $62 per share |

| **Net Loss (2025)** | $4.94 billion |

| **Net Loss (Q1 2026)** | $4.28 billion |

| **AI Business Loss** | $6.4 billion |

| **94x Sales** | Historical underperformance |

*Sources: *

## Part 4: The “Short” Attack—Betting Against the Rocket

The options market is already pricing in further downside.

### The 15% Probability of Halving

Susquehanna analyst Chris Murphy wrote that there was a **15% chance** the stock would lose half its value over the next three months because of option trades . The options market is now allowing investors to bet against the stock for the first time.

### The Meme Stock Vulnerability

Jim Cramer’s diagnosis—that SpaceX “could not sustain its meme status”—captures the fragility of the current stock price . The early rally was driven by retail euphoria, not fundamental analysis. As that enthusiasm fades, the stock is vulnerable to a sharp reversal.

### The $20 Billion Bond Offering

The planned bond offering adds another layer of risk. If the company is taking on debt to fund AI expansion, it signals that the cash burn is not slowing down . More debt means more interest expense, which could widen the losses.

## Part 5: The Investor Playbook—How to Think About SpaceX Stock

The stock is trading at a crossroads. Here is how to think about it.

### For the Long-Term Believer

If you believe in Musk’s vision of a vertically integrated AI powerhouse, the current pullback could be a buying opportunity. The stock is still up over 30% from its IPO price, but it is off its highs . The risk is that the valuation is still stretched, and the cash burn is real.

### For the Short-Term Trader

The volatility is extreme. The options market is pricing in a 15% chance of a 50% decline . Consider defined-risk strategies if you are trading the stock.

### For the Skeptic

Morningstar’s $62 fair value is a warning. The stock is still trading at a significant premium to that estimate. If the AI revenue thesis does not materialize, the downside could be substantial.

| Strategy | Rationale | Risk Level |

| :--- | :--- | :--- |

| **Buy the Dip** | Belief in AI stack integration | High |

| **Wait for Lockup Expiry** | Potential for lower entry point | Moderate |

| **Short the Stock** | Valuation concerns, cash burn | Very High |

| **Do Nothing** | Avoid volatility | Low |

*Sources: *

## Frequently Asked Questions (FAQ)

**Q: Why did SpaceX stock drop after the Cursor acquisition?**

A: SpaceX stock dropped because the $60 billion all-stock acquisition diluted existing shareholders by roughly 3.4%. Additionally, the deal raised concerns about the company’s valuation and cash burn .

**Q: How much market value did SpaceX lose?**

A: SpaceX lost more than **$600 billion** in market value across two trading days, dropping from approximately $3 trillion to $2.37 trillion .

**Q: What is Morningstar’s fair value estimate for SpaceX?**

A: Morningstar lowered its fair value estimate to **$62 per share** following the Cursor deal, from a previous estimate of $63 . In a best-case scenario, the firm says shares could reach $169 if AI revenue improves .

**Q: What is Oppenheimer’s price target for SpaceX?**

A: Oppenheimer analyst Timothy Horan raised his price target to **$250 per share**, up from $190, following the Cursor acquisition .

**Q: Is SpaceX profitable?**

A: No. SpaceX reported a net loss of $4.94 billion in 2025 and another $4.28 billion loss in Q1 2026. The AI business lost $6.4 billion in 2025 .

**Q: What is the lockup expiry and why does it matter?**

A: The lockup expiry occurs in late July, when insider shares become eligible for sale. This could double the stock’s free float and create selling pressure .

**Q: What is the planned bond offering?**

A: SpaceX is planning a bond offering of at least $20 billion to refinance a bridge loan taken out to fund the xAI acquisition. The deal would be the company’s first investment-grade bond issuance .

**Q: Is SpaceX a meme stock?**

A: Some analysts, including Swissquote’s Ipek Ozkardeskaya, have argued that SpaceX has emerged as a meme stock, with investors buying “in the expectation that others will buy too and push the price higher” .

**Q: What did Jim Cramer say about SpaceX?**

A: Jim Cramer posted on X that SpaceX “could not sustain its meme status” and that “looks like it couldn’t sustain the walk-up” .

**Q: When will SpaceX join the S&P 500?**

A: SpaceX will not join the S&P 500 until at least June 2027, due to the index’s 12-month seasoning and profitability requirements .

## Conclusion: The $600 Billion Lesson

We started this article with a number: **$225.64**. That was SpaceX’s peak price—a moment of euphoria that briefly made the company worth nearly $3 trillion.

We end with a different number: **$62**. That is Morningstar’s fair value estimate—a reminder that, for many analysts, the stock is still wildly overvalued.

The $600 billion selloff is a lesson in the volatility of hype-driven stocks. The Cursor acquisition is a strategic bet on AI, but it comes with dilution, debt, and a burning cash pile. The bull case is compelling: SpaceX owns every layer of the AI stack. The bear case is equally compelling: the company is losing billions and trading at 94 times sales.

**For the Investor:**

Do not chase the volatility. The stock is still up over 30% from its IPO price . Wait for the lockup expiry and the first earnings report. That will tell you whether the AI thesis is real or a hallucination.

**For the Trader:**

The options market is pricing in significant volatility. Consider defined-risk strategies if you are trading the stock.

**For the Observer:**

The SpaceX story is a case study in the tension between vision and valuation. Musk is building something extraordinary. But at $2.37 trillion, the market expects extraordinary returns. The question is whether he can deliver.

**The Bottom Line:**

SpaceX stock dropped after the company announced a $60 billion all-stock acquisition of Cursor, wiping out $600 billion in market value. The stock is down roughly 20% from its peak. Morningstar has a fair value estimate of $62, while Oppenheimer has a target of $250. The lockup expiry and a planned bond offering add supply-side pressure. The stock is caught between a valuation chasm and a burning cash pile. How low it goes depends on whether the AI thesis holds—and whether the market believes the vision is worth the price.

---

**#SpaceX #SPCX #ElonMusk #Cursor #AI #IPO #StockMarket #Investing #Valuation**

--read also-

*Disclaimer: This article is for informational purposes only. It does not constitute financial advice. Stock markets are volatile; always consult a licensed professional before making investment decisions.*

The “Peace Dividend” Rally: Why European Stocks Are Outperforming the US for the First Time in Months

 

 The “Peace Dividend” Rally: Why European Stocks Are Outperforming the US for the First Time in Months

**Subtitle:** *From a 1.5% STOXX surge to a 1% S&P drop, the US-Iran deal has flipped the script. Here is why “old economy” Europe is suddenly more attractive than AI-heavy America.*

**Reading Time:** 8 Minutes | **Category:** Markets & Economy

## Introduction: The “Buy Europe” Trade Is Back

For the first time since the Iran war began in February, the narrative has flipped.

European stocks are back in the lead. The Stoxx Europe 600 Index is up about **1.5% this month** as the US and Iran reached an interim deal to reopen the Strait of Hormuz. The S&P 500, by contrast, has dropped **1%** .

The “peace dividend” is fueling a rotation out of the AI-heavy US tech trade and into the cyclical, value-oriented sectors that dominate European markets . After three months of underperformance, Europe’s lack of big artificial intelligence names is suddenly being perceived as an advantage .

“The investment case for the ‘buy Europe’ trade is back,” said Raphael Thuin, head of capital market strategies at Tikehau in Paris . “When you invest in Europe you are diversifying away from the risk in tech.”

In this deep-dive, we will break down the three forces driving Europe’s comeback, analyze why the “stagflation” fears are easing, and explain what this means for your portfolio.

> **The Bottom Line Up Front:** European stocks are outperforming the US for the first time in months, driven by a US-Iran peace deal that is lowering oil prices, easing stagflation fears, and diverting capital away from the overcrowded US tech trade. The Stoxx 600 trades at a 25% discount to the S&P 500, and strategists are rotating into European banks, industrials, and luxury goods. But the rally is fragile—if the ceasefire breaks, Europe’s energy-importing economies will be hit hardest.

## Part 1: The “Peace Dividend” – How the US-Iran Deal Changed the Game

The catalyst for Europe’s comeback is the same force that is reshaping global energy markets: the US-Iran interim agreement and the reopening of the Strait of Hormuz .

### The 30% Oil Crash

Since the deal was announced, oil prices have declined nearly **30%** . Brent crude has fallen from its war-time peaks above $100 to roughly $77 a barrel . The strait’s reopening has restored the flow of roughly 11 million barrels a day of Gulf crude, easing the most severe energy shock in decades .

For Europe, which imports most of its oil and has spent years reconfiguring gas supplies away from Russia, this is a lifeline . An energy price spike translates directly into weaker margins and slower consumer spending. The price drop is the opposite .

### The “Stagflation” Risk Eases

The easing of energy prices has dramatically reduced the risk of stagflation—the combination of high inflation and weak growth that haunted European markets in 2022 .

Eurozone inflation ticked up to 3.2% in May, but the market is betting that the reopening of the strait will lower energy inflation for a quarter or two . While the ECB remains hawkish, the worst-case scenario—a 2022-style energy spiral—is off the table .

| Metric | Before Iran Deal | After Iran Deal |

| :--- | :--- | :--- |

| **Oil Price (Brent)** | ~$100+ | ~$77 |

| **Stoxx 600 Performance (Month)** | Underperforming | +1.5% |

| **S&P 500 Performance (Month)** | Outperforming | -1% |

| **Stagflation Risk** | High | Easing |

| **Energy Price Volatility** | Extreme | Moderating |

*Sources: *

## Part 2: The “Old Economy” Advantage – Why Europe Is Winning

The second force driving Europe’s comeback is a structural shift in investor preferences.

### The AI Fatigue Factor

For two years, the US tech trade has been the dominant force in global markets. The Magnificent Seven—Apple, Microsoft, Nvidia, Alphabet, Amazon, Meta, Tesla—have driven the S&P 500 to record highs.

But the AI trade is showing signs of fatigue. SpaceX’s massive IPO, while exciting, is also draining liquidity from other tech names. The chip sector is crowded. And the valuations are stretched .

Europe’s lack of big AI names is now a feature, not a bug . The Stoxx 600 is heavily weighted toward banks, automakers, industrial goods, and luxury brands—sectors that benefit from lower oil prices and stronger economic growth .

### The Valuation Gap

European stocks continue to screen attractively against their US peers. The Stoxx Europe 600 trades at a forward price-to-earnings ratio of **15 times**, a **25% discount** to the S&P 500 .

This discount reflects legitimate risks—Europe’s growth is weaker, its fiscal unity is thinner, and its exposure to energy shocks is greater . But the gap also represents an opportunity for investors who believe the risks are priced in.

### The Rotation Trade

Investors have been quick to rotate into growth-sensitive sectors in Europe. Banks, industrial goods, and media stocks were among the strongest performers in the week since the interim deal was announced. The more defensive utilities and telecom stocks have lagged .

Market participants are also shunning high-flying energy stocks as they recalibrate the outlook for oil prices . Morgan Stanley has downgraded the energy sector to equal-weight while adding to its overweight in banks .

| Sector | Post-Deal Performance | Outlook |

| :--- | :--- | :--- |

| **Banks** | Strong | Overweight (Morgan Stanley) |

| **Industrials** | Strong | Attractive (RBC) |

| **Luxury Goods** | Strong | Brightening |

| **Utilities** | Lagging | Defensive |

| **Telecom** | Lagging | Defensive |

| **Energy** | Selling | Downgraded |

*Sources: *

## Part 3: The “Structural” Adaptation – Why Europe Is Less Vulnerable

One of the most surprising findings from the recent data is that Europe is less vulnerable to an energy shock than many investors assume.

### The Energy Intensity Gap

According to an RBC Global Asset Management analysis, the UK and France consume roughly **50% less oil and natural gas per dollar of economic output** than the United States . This reflects Europe’s growing reliance on renewable energy and nuclear power .

The shock from the 2022 energy crisis was so painful that firms and households cut consumption, diversified sources, and invested in efficiency . The current shock is therefore less likely to ignite the kind of broad inflation spiral that forced the ECB’s hand four years ago .

### The Fiscal Cushion

European governments have also started to subsidize heightened energy costs, reducing economic pressures. Over half of eurozone member states were on track to meet the 3% of GDP budget deficit threshold in 2026, including Italy and Greece—countries that had previously struggled with finances .

This fiscal discipline provides a cushion against a prolonged energy shock.

### The Reconfiguration

Europe’s energy supply has been reconfigured away from Russia since 2022. Gas demand remains below pre-crisis levels, particularly in industry and households . The continent is better prepared for a supply shock than it was four years ago.

## Part 4: The “Skeptics” – Why Some Investors Are Not Buying the Rally

Despite the optimism, not everyone is convinced.

### The “Narrow Channel” Risk

The European stock rally of the past few months rests on a single geopolitical fact: oil tankers are flowing through the Strait of Hormuz again . But the strait remains a flashpoint. Iran says it has reopened the passage, but the American blockade on Iranian shipping remains in place . Any fresh escalation could quickly shut the channel again .

“The market has priced in a benign outcome and has not done enough to prepare for the alternative,” warns a recent analysis .

### The Structural Inflation Problem

The inflation the ECB is fighting is partly structural, not just geopolitical. Labour-market tightness, wage growth above productivity, and fiscal stimuli in several large euro-area economies have kept price pressures alive even before the Hormuz crisis added fuel .

The strait’s reopening may lower energy inflation for a quarter or two. It will not resolve the wage-price dynamics that keep the ECB on the tightening path .

### The Hawkish ECB

The European Central Bank is widely expected to raise rates later this year, with markets pricing in a follow-up hike in September . Higher borrowing costs threaten to weigh on business investment and consumer spending .

A recent Bank of America survey showed a net 4% of fund managers expect regional stocks to decline over the coming months, the most bearish reading since September 2024 .

| Skeptic Argument | Details |

| :--- | :--- |

| **Geopolitical Fragility** | The Hormuz reopening could be reversed by fresh escalation  |

| **Structural Inflation** | Wage-price dynamics remain a concern  |

| **ECB Hawkishness** | The central bank is likely to hike further  |

| **Earnings Risk** | A growth slowdown could collapse the earnings story  |

## Part 5: The Investor Playbook – How to Trade the “Peace Dividend”

The market is rotating into Europe. Here is how to position.

### For the Long-Term Investor

The case for European equities has matured. It is no longer the contrarian bet on cheapness. It is a bet that Europe’s institutions, central bank, and firms have adapted to a more volatile energy environment .

Consider adding exposure to European banks, which offer attractive valuations and positive earnings momentum, and industrial companies, which benefit from structural tailwinds such as the push for strategic autonomy and defense spending .

### For the Tactical Trader

The “buy the dip” mentality remains intact. Each pullback over the past week has attracted fresh demand, preventing a deeper correction from taking hold .

But the rally is fragile. Consider defined-risk strategies if you are trading the rotation. The VIX is elevated, and options premiums are attractive.

### For the Thematic Investor

Consider rotating out of overvalued US tech stocks and into European value stocks. The Stoxx 600’s discount to the S&P 500 is still significant .

Banks are the most direct play on the peace dividend. Industrials are a hedge against a resurgent European economy. Luxury goods benefit from lower inflation and stronger consumer confidence.

| Asset Class | Recommended Action | Rationale |

| :--- | :--- | :--- |

| **European Banks** | Overweight | Cheap valuations, positive earnings  |

| **European Industrials** | Overweight | Structural tailwinds  |

| **European Luxury Goods** | Overweight | Consumer confidence  |

| **US Tech** | Underweight | Overcrowded, valuation risk |

| **Energy Stocks** | Reduce | Oil price downside  |

## Frequently Asked Questions (FAQ)

**Q: Why are European stocks outperforming the US right now?**

A: European stocks are outperforming because the US-Iran peace deal has lowered oil prices, easing stagflation fears in energy-importing Europe. Additionally, the US tech trade is faltering on worries the rally has gone too far, and Europe’s lack of big AI names is now a feature, not a bug .

**Q: How much has oil fallen since the Iran deal?**

A: Oil prices have declined nearly 30% in the past month. Brent crude has fallen from war-time peaks above $100 to roughly $77 a barrel .

**Q: What is the valuation gap between European and US stocks?**

A: The Stoxx Europe 600 trades at a forward price-to-earnings ratio of 15 times, a 25% discount to the S&P 500 .

**Q: Is the stagflation risk in Europe really easing?**

A: The easing of energy prices has dramatically reduced the risk of stagflation. While inflation remains elevated at 3.2%, the market is betting that the reopening of the strait will lower energy inflation .

**Q: Is the ECB going to raise rates?**

A: Yes. The ECB is widely expected to raise its key deposit rate by 25 basis points to 2.25%, with markets pricing in a follow-up hike in September .

**Q: What is the biggest risk to the European rally?**

A: The biggest risk is that the ceasefire breaks. If the Strait of Hormuz closes again, oil prices will spike, inflation will rise, and the ECB will be forced to hike aggressively. Europe’s energy-importing economies would be hit hardest .

**Q: What sectors are benefiting from the peace dividend?**

A: Banks, industrial goods, and media stocks were among the strongest performers in the week since the interim deal was announced. Luxury goods are also expected to benefit from easing inflation .

**Q: Is Europe less vulnerable to energy shocks than before?**

A: Yes. Europe has reduced its energy intensity since 2022. The UK and France consume roughly 50% less oil and gas per dollar of economic output than the United States .

**Q: Should I buy European stocks now?**

A: (Disclaimer: Not financial advice.) European stocks offer attractive valuations and a growing catalyst in the peace dividend. But the rally is fragile and dependent on the ceasefire holding. Consider adding exposure to European banks and industrials, but be prepared for volatility.

## Conclusion: The “Peace Dividend” Is Real – But Fragile

We started this article with a number: 1.5%. That is how much the Stoxx 600 has gained this month.

We end with a different number: **25%**. That is the discount at which European stocks still trade relative to their US peers.

The European rally is real. The peace dividend is real. The rotation out of tech is real. But the rally is also fragile. It rests on a single geopolitical fact: oil tankers are flowing through the Strait of Hormuz again. If the ceasefire breaks, the rally will break with it .

**For the Investor:**

European stocks offer an attractive entry point. The valuations are reasonable. The catalysts are real. But the risks are also real. Diversify your exposure and be prepared for volatility.

**For the Trader:**

The “buy Europe” trade is gaining momentum. But it is not a straight line. Consider defined-risk strategies if you are trading the rotation.

**For the Skeptic:**

The European rally is not based on wishful thinking. It is based on real factors: lower oil prices, easing stagflation fears, and a shift in investor preferences away from overcrowded US tech . But it is also fragile. Watch the Strait of Hormuz. It will tell you which direction the market is heading.

**The Bottom Line:**

European stocks are back in the lead as stagflation risks ease. The US-Iran peace deal has lowered oil prices, and investors are rotating into Europe’s cyclical sectors. But the rally is fragile. If the ceasefire breaks, Europe’s energy-importing economies will be hit hardest. The “peace dividend” is real—but it is not guaranteed.

---

**#EuropeanMarkets #Stoxx600 #IranDeal #OilPrices #ECB #Stagflation #Investing #PeaceDividend**

read also---

*Disclaimer: This article is for informational purposes only. It does not constitute financial advice. Stock markets are volatile; always consult a licensed professional before making investment decisions.*